Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis;Patogenetyczne uzasadnienie stosowania statyn w profilaktyce udaru niedokrwiennego mózgu w oewietle zapalnej teorii rozwoju miażdżycy

Neurologia i Neurochirurgia Polska

Volumn 46, Issue 2, 2012, Pages 176-183

  Kotlȩga, Dariusz ^a   Ciećwiez, Sylwester ^a   Turowska Kowalska, Jolanta ^a   Nowacki, Przemyław ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

C reactive protein; Inflammation; Pleiotropic effect; Statins; Stroke

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84860777325     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2012.28261     Document Type: Review

References (87)

1. Truelsen T., Piechowski-Jóźwiak B., Bonita R. i wsp. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13: 581-598.
2. Warlow C., Sudlow C., Dennis M. i wsp. Stroke. Lancet 2003; 362: 1211-1224.
3. Sacco R.L., Adams R., Albers G. i wsp. Guidelines for pre - vention of stroke in patients with ischemic stroke or transient ischemic attack: A Statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
4. Stary H.C., Chandler A.B., Dinsmore R.E. i wsp. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1373.
5. Stoll G., Bendszus M. Inflammation and atherosclerosis. Novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-1932.
6. Puddu G.M., Cravero E., Arnone G. i wsp. Molecular aspects of atherogenesis: new insights and unsolved questions. J Biomed Sci 2005; 12: 839-853.
7. Amarenco P., Labreuche J., Lavallee P. i wsp. Statins in stroke prevention and carotid atherosclerosis: systematic review and upto-date meta-analysis. Stroke 2004; 35: 2902-2909.
8. Sanossian N., Ovbiagele B. Drug insight: translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol 2008; 4: 43-49.
9. Ovbiagele B. Statin therapy after stroke or transient ischemic attack: a new weapon in our secondary stroke prevention arsenal? Nat Clin Pract Neurol 2007; 3: 130-131.
10. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S. i wsp. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-2152.
11. Bansal S., Buring J.E., Rifai N. i wsp. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316.
12. Amarenco P., Bogousslavsky J., Callahan A.S. i wsp. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 2003; 16: 389-395.
13. Amarenco P., Goldstein L.B., Szarek M. i wsp. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: 3198-3204.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cho - lesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
15. Wasserman B.A., Sharrett A.R., Lai S. i wsp. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the Multi- Ethnic Study of Atherosclerosis (MESA). Stroke 2008; 39: 329-335.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
17. Emberson J., Bennett D., Link E. i wsp. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011; 377: 469-476.
18. Ridker P.M., Danielson E., Fonseca F.A. i wsp. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
19. Bots M.L., Hoes A.W., Koudstaal P.J. i wsp. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-1437.
20. Aminbakhsh A., Mancini G.B. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin Invest Med 1999; 22: 149-157.
21. Crouse J.R. III, Raichlen J.S., Riley W.A. i wsp. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-1353.
22. Kastelein J.J., Akdim F., Stroes E.S. i wsp. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.
23. Furberg C.D., Adams H.P., Applegate W.B. i wsp. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-1687.
24. Salonen R., Nyyssönen K., Porkkala E. i wsp. Kuopio Athe - rosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.
25. Mercuri M., Bond M.G., Sirtori C.R. i wsp. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627-634.
26. Smilde T.J., Van Wissen S., Wollersheim H. i wsp. Effect of aggressive versus conventional lipid lowering on atherosclerosis pro gression in familial hypercholesterolaemia (ASAP): A pro - spective, randomised, double-blind trial. Lancet 2001; 357: 577-581.
27. Hodis H.N., Mack W.J., LaBree L. i wsp. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized, controlled clinical trial. Ann Int Med 1996; 124: 548-556.
28. MacMahon S., Sharpe N., Gamble G. i wsp. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the lipid atherosclerosis substudy. Circulation 1998; 97: 1784-1790.
29. Anderssen S. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005; 178: 387-397.
30. Libby P., Ridker P.M., Maseri A. Inflammation and athero - sclerosis. Circulation 2002; 105: 1135-1143.
31. Haverkate F., Thompson S.G., Pyke S.D. i wsp. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
32. Toss H., Lindahl B., Siegbahn A. i wsp. Prognostic influence of increased fibrinogen and c-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96: 4204-4210.
33. Schillinger M., Exner M., Mlekusch W. i wsp. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation 2005; 111: 2203-2209.
34. Lusis A.L. Atherosclerosis. Nature 2000; 407: 233-241.
35. Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
36. Andersson J., Johansson L., Ladenvall P. i wsp. C-reactive pro - tein is a determinant of first-ever stroke: prospective nested casereferent study. Cerebrovasc Dis 2009; 27: 544-551.
37. Ladenvall C., Jood K., Blomstrand C. i wsp. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 2006; 37: 2018-2023.
38. Ridker P.M., Cuchman M., Stampfer M.J. i wsp. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
39. Wakugawa Y., Kiyohara Y., Tanizaki Y. i wsp. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke In a general Japanese population. The Hisayama Study. Stroke 2006; 37: 27-32.
40. Lip G.Y.H., Patel J.V., Hughes E. i wsp. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with non - valvular atrial fibrillation. Relationship to stroke risk factors, stroke risk stratification schema and prognosis. Stroke 2007; 38: 1229-1237.
41. Schlager O., Exner M., Mlekusch W. i wsp. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke 2007; 38: 1263-1268.
42. Ridker P.M., Rifai N., Rose L. i wsp. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
43. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-1973.
44. Elkind M.S.V., Coates K., Tai W. i wsp. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurology 2006; 6: 37.
45. Engelmann M.D., Svendsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
46. Chung M.K., Martin D.O., Sprecher D. i wsp. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
47. Acevedo M., Cobalan R.L., Perez L. i wsp. C-reactive protein in atrial fibrillation: evidence for the presence of inflammation in the genesis and perpetuation of the arrhythmia. J Am Coll Cardiol 2003; 41: 1089-1094.
48. Sata N., Hamada N., Horinouchi T. i wsp. C-reactive protein and atrial fibrillation. Jpn Heart J 2004; 45: 441-445.
49. Anderson J.L., Maycock C.A., Lappe D.L. i wsp. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004; 94: 1255-1259.
50. Dernellis J., Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56: 375-380.
51. Boos C.J., Anderson R.A., Lip G.Y.H. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-149.
52. Psychari S.N., Apostolou T.S., Sinos L. i wsp. Relation of ele - vated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-767.
53. Roldán V., Marin F., Martinez J.G. i wsp. Relation of inter - leukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005; 95: 881-882.
54. Aguilar-Salinas C.A., Barrett H., Schonfeld G. Metabolic modes of action of the statins in the hiperlipoproteinemias. Atherosclerosis 1998; 141: 203-207.
55. Gaw A., Packard C.J., Murray E.F. i wsp. Effects of simvasta - tin on ApoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993; 13: 170-189.
56. Toth P.P., Davidson M.H. Leczenie dużymi dawkami statyn: korzyści i bezpieczeństwo intensywnej terapii hipolipemizuja,cej. Forum Medycyny Rodzinnej 2009; 3: 234-245.
57. Gasior M., Czekaj A., Przybylska K. i wsp. Plejotropowe dzia - łanie statyn. Choroby Serca i Naczyń 2008; 5: 141-145.
58. Jialal I., Stein D., Balis D. i wsp. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
59. Adamson P, Greenwood J, How do statins control neuro - inflammation? Inflamm Res 2003; 52: 399-403.
60. Sakoda K., Yamamoto M., Negishi Y. i wsp. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 2006; 85: 520-523.
61. Ovbiagele B., Saver J.L., Starkman S. i wsp. Statin enhancement of collateralization in acute stroke. Neurology 2007; 68: 2129-2131.
62. Stuve O., Youssef S., Dunn S. i wsp. Statins as potential thera - peutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003; 16: 393-401.
63. Davignon J., Leiter A.L Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005; 1: 29-40.
64. Undas A., Brummel-Ziedins K.E., Mann K.G. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-294.
65. Aviram M., Rosenblat M., Bisgaier C.L. i wsp. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.
66. Girona J., La Ville A.E., Sola R. i wsp. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-851.
67. Endres M., Laufs U., Liao J.K. i wsp. Targeting eNOS for stroke protection. Trends Neurosci 2004; 27: 283-289.
68. Bellosta S., Arnaboldi L., Gerosa L. i wsp. Statins effect on smooth muscle cell proliferation. Semin Vasc Med 2004; 4: 347-356.
69. Filipiak K., Opolski G. Leki stabilizuja,ce blaszke, miażdżycowa, - teraźniejszość i przyszłość. Przew Lek 2000; 7: 32-38.
70. Davies M.E., Harrison D.G. Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation 2001; 103: 2-4.
71. Pearson T.A., Mensah G.A., Alexander R.W. i wsp. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
72. Wissen S., Trip M D., Smilde T.J. i wsp. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-366.
73. Avellone G., Di Garbo V., Campisi D. i wsp. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease. Int Angiol 2006; 25: 26-34.
74. Collins R., Armitage J., Parish S. i wsp. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
75. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
76. Bybee K.A., Wright R.S., Williams B.A. i wsp. Effect of con - comitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 771-774.
77. Aronow H.D., Topol E.J., Roe M.T. i wsp. Effect of lipidlowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-1068.
78. Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
79. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
80. Heeschen C., Hamm C.W., Laufs U. i wsp. Withdrawal of statins increases event rates in patients with acute coronary syndrome. Circulation 2002; 105: 1446-1452.
81. Fonarow G.C., Wright R.S., Spencer F.A. i wsp. National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611-616.
82. Li J.J., Li Y.S., Chu J.M. i wsp. Changes of plasma infla - mmatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 2006; 366: 269-273.
83. Huang C.Y., Wu T.C., Lin W.T. i wsp. W. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercho - lestero laemic patients. Eur J Clin Invest 2006; 36: 76-84.
84. Rosengarten B., Auch D., Kaps M. Effects of initiation and acute withdrawal of statins on the neurovascular coupling mechanism in healthy, normocholesterolemic humans. Stroke 2007; 38: 3193-3197.
85. Lee K.T., Lai W.T., Chu C.S. i wsp. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004; 102: 166-170.
86. Blanco M., Nombela F., Castellanos M. i wsp. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69: 904-910.
87. Colivicchi F., Bassi A., Santini M. i wsp. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652-2657.